Understand one of the most common concerns about clinical trial design.
This is the #1 question patients ask about clinical trials. The thought of receiving something that isn't the actual treatment is scary, especially if you have a serious disease. It's a completely legitimate concern, and it deserves a straight answer: yes, placebos are sometimes used, and you should understand what that means.
A placebo is a dummy treatment—often a pill with no active ingredient, or a saline injection that looks like the real drug. Researchers use placebos to separate the actual effect of the treatment from the psychological effect of receiving something. If people believe they're getting a real treatment, their symptoms might improve just because they expect them to. Placebos help identify whether the actual drug is responsible for improvement.
Here's something important many patients don't know: many rare disease trials do NOT use placebos. Why? Because in rare disease research, there is often no standard treatment to compare against. If your disease is so uncommon that there isn't an established therapy, it would be unethical to give a placebo. You wouldn't be compared against "nothing." Instead, the trial either compares the new treatment to the best available standard care (if one exists) or everyone in the trial gets the experimental treatment.
Look for the word "open-label" in the trial description. An open-label trial means everyone knows they're getting the real treatment. There's no placebo arm. This is extremely common in rare disease trials.
Many trials that do use placebos have an "open-label extension." This means that after the main trial ends, everyone—including those who received placebo—gets access to the actual drug. It's not a perfect solution to the placebo concern, but it's important. You could enroll in a trial that has a placebo phase, but you know that if the drug works, you'll have access to it afterward.
Always ask the trial coordinator about this before you enroll. Specifically ask: Is there a placebo arm? If so, is there an open-label extension? Can I continue the treatment after the trial if it works?
Randomization means participants are assigned to treatment groups by chance, not by choice. This removes bias. If people could choose which group to join, sicker people might flock to what they think is the real drug, skewing the results.
Blinding means you don't know whether you're getting the treatment or the placebo. (Researchers don't know either, in a "double-blind" trial.) This prevents the placebo effect from confusing the results. Your expectation that you're getting a real drug shouldn't influence your outcome.
In a single-blind trial, you don't know what you're getting, but researchers do. In a double-blind trial, neither you nor the researchers know until the trial is over. Double-blind is considered stronger science.